This approach was implemented using a novel nanocarrier system, where red blood cell membrane (RBCM)-coated NPs were further functionalized with the tumor-targeting peptide glypican-3 (GPC3) to achieve precise tumor-targeted delivery. This evidence concerns the gene GPC3 and neoplasm.